353 related articles for article (PubMed ID: 34217580)
1. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
Cabıoğlu N; Karanlık H; Yıldırım N; Müslümanoğlu M; Çakmak Karadeniz G; Trabulus Can D; Tükenmez M; Ersoy YE; Uras C; Zengel B; Emiroğlu S; Polat AK; Yeniay L; Özkurt E; Kara H; İbiş K; Aydıner A; Özmen V; İğci A
Eur J Surg Oncol; 2021 Oct; 47(10):2506-2514. PubMed ID: 34217580
[TBL] [Abstract][Full Text] [Related]
2. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
[TBL] [Abstract][Full Text] [Related]
3. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF
Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
5. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
[TBL] [Abstract][Full Text] [Related]
8. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
9. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
Fernandez-Gonzalez S; Falo C; Pla MJ; Campos M; Ortega-Exposito C; Ortega R; Vicente M; Petit A; Bosch-Schips J; Bajen MT; Reyes G; Martínez E; González-Viguera J; Peñafiel J; Stradella A; Pernas S; Ponce J; Garcia-Tejedor A
Breast Cancer Res Treat; 2024 Jul; 206(1):131-141. PubMed ID: 38635082
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
[TBL] [Abstract][Full Text] [Related]
12. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of sentinel lymph node biopsy prior to axillary lymph node dissection: the role of isolated tumor cells/micrometastases and multifocality/multicentricity-a retrospective study of 1214 breast cancer patients.
Schröder L; Fricker R; Stein RG; Rink T; Fitz H; Blasius S; Wöckel A; Müller T
Arch Gynecol Obstet; 2018 Jun; 297(6):1509-1515. PubMed ID: 29594495
[TBL] [Abstract][Full Text] [Related]
16. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
18. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
20. Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
Chun JW; Kim J; Chung IIY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Breast Cancer Res Treat; 2021 Jun; 187(3):647-655. PubMed ID: 33966181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
